Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Zymeworks to acquire Theravance for $17 cash per share plus one non-tradeable CVR, implying substantial upfront shareholder value.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Zymeworks to acquire Theravance for $17 cash per share plus one non-tradeable CVR, implying substantial upfront shareholder value
- CVRs provide 80% of ampreloxetine licensing proceeds, a $50 million milestone, and 10% of net sales royalties
- Closing targeted for second half of 2026, subject to two-thirds shareholder approval, HSR clearance, and customary conditions
- $32.515 million termination fees apply to specified deal failures, including superior proposals, recommendation changes, or unresolved HSR conditions
- $350 million senior secured notes commitment from OMERS Life Sciences, combined with cash on hand, to finance the acquisition
Item 7.01 · Regulation FD Disclosure
- Disclosure flags proposed Theravance merger, financing, restructuring, and anticipated milestone payments as key execution dependencies
- Strategic flexibility depends on R&D investment capacity, strategic opportunities, and potential capital returns to stockholders
- Future value tied to YUPELRI sales, Trelegy royalty interests, collaboration royalties, and zanidatamab commercialization
- Principal risks include merger failure, financing issues, regulatory delays, clinical setbacks, and missed Trelegy sales milestones
Item EX-99.1 · Exhibit EX-99.2
- Acquisition of Theravance for $17 per share, approximately $929 million cash consideration, expected closing in second half 2026
- Adds 35% U.S. YUPELRI profit share, generating approximately $60 million annualized cash flow at current run-rates
- YUPELRI U.S. sales reached $266.6 million in 2025, up 12%, with April 2039 generic launch settlements
- Financing includes $350 million non-recourse OMERS note, $219 million Zymeworks cash, and approximately $360 million Theravance net cash
- Strategic upside includes $100 million TRELEGY milestone expected in Q1 2027, approximately $2.5 billion Irish tax attributes, and potential cost synergies
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.